![Janet Dorling](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Janet Dorling
Corporate Officer/Principal bij
GILEAD SCIENCES, INC.
Profiel
Janet Dorling is currently the Director at Gilead Sciences Belgium BV and the Senior VP- Intercontinental Region at Gilead Sciences, Inc. She previously worked as the Director at CymaBay Therapeutics, Inc. from 2021 to 2024, the VP-Breast Cancer Franchise & Global Product at Roche Holding AG from 2015 to 2017, the Chief Commercial Officer at CymaBay Therapeutics, Inc. in 2019, and the Chief Commercial Officer at Achaogen, Inc. from 2017 to 2019.
Ms. Dorling has a graduate degree from Duke University and an MBA from the University of California, Berkeley's Haas School of Business.
Actieve functies van Janet Dorling
| Bedrijven | Functie | Begin |
|---|---|---|
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01-05-2020 |
Gilead Sciences Belgium BV
 Gilead Sciences Belgium BV Medical DistributorsDistribution Services Wholesales pharmaceutical products | Directeur/Bestuurslid | 01-02-2023 |
Eerdere bekende functies van Janet Dorling
| Bedrijven | Functie | Einde |
|---|---|---|
| CYMABAY THERAPEUTICS, INC. | Directeur/Bestuurslid | 22-03-2024 |
| CYMABAY THERAPEUTICS, INC. | Corporate Officer/Principal | 01-12-2019 |
| ACHAOGEN | Corporate Officer/Principal | 30-06-2019 |
| ROCHE HOLDING AG | Corporate Officer/Principal | 01-01-2017 |
Opleiding van Janet Dorling
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
42
Eerstegraads connecties
8
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 8 |
|---|---|
Gilead Sciences, Inc.
 Gilead Sciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes therapeutic products and treatments for life threatening diseases | Health Technology |
Roche Holding AG
 Roche Holding AG Pharmaceuticals: MajorHealth Technology Operates as a research-focused healthcare company with combined focus in pharmaceuticals and diagnostics | Health Technology |
CymaBay Therapeutics, Inc.
 CymaBay Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for people with life-threatening diseases | Health Technology |
Achaogen, Inc.
 Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Operates as a a biopharmaceutical company, which engages in the research, development, and commercialization of antibacterial treatments for multi-drug resistant (MDR) gram-negative infections | Health Technology |
Duke University
 Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Haas School of Business
 Haas School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Gilead Sciences Belgium BV
Gilead Sciences Belgium BV Medical DistributorsDistribution Services Wholesales pharmaceutical products | Distribution Services |
